Fox Run Management L.L.C. Buys New Position in United Therapeutics Co. (NASDAQ:UTHR)

Fox Run Management L.L.C. bought a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,216 shares of the biotechnology company's stock, valued at approximately $429,000.

Other large investors have also bought and sold shares of the company. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics during the fourth quarter worth $25,000. Brooklyn Investment Group acquired a new position in United Therapeutics during the 3rd quarter worth about $33,000. Millstone Evans Group LLC bought a new stake in United Therapeutics during the 4th quarter worth about $67,000. MassMutual Private Wealth & Trust FSB increased its position in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 58 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its stake in shares of United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after acquiring an additional 258 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Nilda Mesa sold 255 shares of the firm's stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now owns 5,528 shares of the company's stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now owns 8,480 shares of the company's stock, valued at $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,755 shares of company stock valued at $29,792,021. 11.90% of the stock is owned by company insiders.

Remove Ads

United Therapeutics Trading Down 0.3 %

Shares of UTHR stock traded down $1.05 on Friday, reaching $306.97. The company had a trading volume of 223,177 shares, compared to its average volume of 450,767. The stock has a market cap of $13.79 billion, a PE ratio of 13.48, a PEG ratio of 0.97 and a beta of 0.64. The company has a 50-day moving average of $340.06 and a 200-day moving average of $355.78. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter in the prior year, the firm earned $4.36 earnings per share. Sell-side analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on UTHR. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Finally, HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.